| Trial ID # | NCT00087087 |
| Phase | II |
| Drug Class | Chemotherapy |
| Drug Name | Pemetrexed |
| Alternate Drug Names | Pemetrexed disodium, Alimta |
| Drugs in Trial | Pemetrexed |
| Eligible Participant | Primary platinum resistant or refractory ovarian cancer |
| Patients Enrolled | 51; median 4 prior therapies |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, PFS, OS, evaluated per RECIST |
| Efficacy | ORR: 21% (1CR, 9PR) |
| Clinically Significant Adverse Events | Serious AE: none |
| Conclusion | Favorable antitumor activity with mild and non-cumulative toxicity |
| Reference | Miller DS et al. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol (2009) 27(16):2686-91 |